Pharmaceutical Video Surveillance: FDA, GMP & Video Retention Considerations
For pharmaceutical manufacturers, security camera footage can serve a much bigger purpose than physical security. It can help Quality Assurance (QA) teams review production processes, investigate deviations, and verify critical activities during batch release.
But when does video surveillance footage become a regulated GMP record, and how long should it be retained?
The FDA does not impose a universal CCTV retention period on pharmaceutical facilities. However, where footage forms part of a required batch-specific production, control, or distribution record, 21 CFR § 211.180(a) generally requires retention for at least one year after the batch's expiration date.
That could mean keeping selected recordings for six years or longer, while general security cameras follow a shorter retention schedule. The key is understanding which recordings support GMP activities and designing storage systems around those requirements.
For the broader framework, visit our Security Camera Video Retention Hub.
Does the FDA Require Security Cameras in Pharmaceutical Manufacturing?
No. FDA drug Current Good Manufacturing Practice (CGMP) regulations do not impose a general requirement to install security cameras in pharmaceutical manufacturing facilities.
However, the FDA recognizes that video can be useful for monitoring and evaluating aseptic manufacturing processes.
Its Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing identifies video recording as a useful aid for reviewing personnel practices during media fills and assessing airflow studies.
The distinction matters: video is not universally required, but once a manufacturer relies on it for quality-related activities, the footage and its reliability may become relevant to FDA inspections.
In a 2026 Form FDA 483 issued to Eugia Pharma Specialities, investigators observed that CCTV was the primary method used by QA personnel to review filling operations. However, they also identified activities that existing cameras and viewing windows could not adequately capture.
Footage review, including a smoke-study video, found that certain activities were not clearly visible due to camera positioning. These observations highlight why camera coverage, image quality, and the ability to review critical interventions are key elements of an effective pharmaceutical surveillance strategy.
The Form 483 relates to a separate, later inspection of Eugia Pharma Specialities, which also received an FDA warning letter in 2024 concerning video retention and other manufacturing deficiencies. A Form 483 records investigator observations and does not constitute a final FDA determination.
When Does Production Video Become a GMP Record?
Not every recording made inside a pharmaceutical facility is a GMP record.
The distinction depends on how the footage is used and whether it supports a record required by applicable regulations, sometimes called predicate rules.
Under the FDA's Part 11 guidance, electronic record requirements can apply when a manufacturer maintains required records electronically or relies on electronic records to perform regulated activities.
Examples of footage that may support GMP records include:
- QA review of aseptic interventions during batch release.
- Media-fill and process-simulation recordings.
- Smoke-study videos used to evaluate airflow.
- Footage supporting deviation investigations.
By comparison, cameras monitoring parking lots, offices, perimeter fences, or general warehouse activity usually serve a physical security purpose rather than supporting GMP records.
A practical first step is to document which cameras support which quality records. QA teams should develop procedures identifying the intended use of recordings, the applicable retention period, and whether electronic footage forms part of the regulated record.
Medical Devices: Different Regulatory Considerations
Medical device manufacturers should not automatically apply pharmaceutical drug batch-record retention rules to their operations.
Since February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has incorporated ISO 13485:2016 into its medical device quality system requirements. Device manufacturers must therefore assess their record retention obligations under the applicable QMSR and ISO 13485 record-control requirements rather than relying on pharmaceutical drug retention periods.
For connected devices, medical device cybersecurity also presents distinct considerations. FDA cybersecurity guidance addresses potential risks such as cyber threats, known vulnerabilities, cybersecurity vulnerabilities, and incident response.
These requirements should not be confused with CCTV retention rules. However, both highlight the importance of secure systems, controlled access, reliable data, and documented procedures.
How Long Should Pharmaceutical Manufacturers Keep Video?
Under 21 CFR § 211.180(a), required batch-specific production, control, and distribution records generally must be retained for at least one year after the batch's expiration date.
For example, footage forming part of a required record for a product with a five-year shelf life may need six years of retention (5+1).
For certain OTC drug products without expiration dating, the regulation specifies a different period: three years after distribution.
Importantly, these requirements do not automatically apply to every pharmaceutical security camera.
What the FDA Said About Video Retention
In its August 2024 warning letter to Eugia Pharma Specialities, following an inspection of the company's Unit III facility, the FDA found Eugia's corrective response inadequate because it did not explain how the proposed video retention period would allow sufficient QA review of production and cleaning activities as part of batch release, in accordance with 21 CFR § 211.180(a).
This demonstrates that where video is relied upon for regulated quality activities, retention becomes more than a general security decision.
The warning letter and the 2026 Form FDA 483 discussed earlier concern separate inspections of Eugia Pharma Specialities and should not be interpreted as findings involving two different manufacturers.
SCW in Action: Long-Term Storage for Guerbet
Guerbet, an injectable pharmaceutical manufacturer, needed selected cameras to retain footage for the product's expiration period plus one year so recordings would remain available for batch review.
SCW designed a dedicated long-term storage system to meet that requirement.
A Tiered Video Retention Policy for Pharmaceutical Facilities
A camera-by-camera approach helps manufacturers maintain required footage without storing every recording for years.
| Camera group | Purpose | Starting retention |
|---|---|---|
| Fill rooms and critical aseptic interventions | QA batch-release review | Expiry + 1 year where footage forms part of required batch records |
| Media-fill and smoke-study recordings | Process simulation and airflow assessment | Retain with the study record under QA procedures |
| Packaging and labeling lines | Deviations and complaints | Per QA procedures and applicable record requirements |
| Warehouse and loading docks | Shipping, receiving, and theft investigations | 30 days or longer based on claims and contracts |
| Perimeter, parking, and offices | General security | 30 days as a starting point |
These are examples, not universal legal requirements. The manufacturer's QA unit should determine which cameras support GMP records and establish appropriate retention procedures.
Access Control, Audit Trails & Regulated Electronic Records
When video qualifies as a Part 11 electronic record, 21 CFR § 11.10 establishes controls for electronic record systems.
These include the ability to produce accurate and complete copies, protect records throughout the required retention period, limit access to authorized individuals, and maintain secure, time-stamped audit trails.
Additionally, 21 CFR § 211.180(c) requires records covered by Part 211 to remain readily available for authorized inspection throughout their retention period at the establishment where the recorded activities occurred. Records that can be immediately retrieved electronically can satisfy this requirement.
For pharmaceutical manufacturers, practical considerations include:
- Defining who can view, export, modify, or delete recordings.
- Documenting how footage is retrieved and exported for QA review.
- Maintaining accurate recorder timestamps.
- Regularly testing the ability to retrieve older recordings, particularly where footage must be retained for several years.
- Protecting recording systems and software against unauthorized access.
These requirements reinforce why long-term pharmaceutical video retention involves more than simply providing enough storage capacity. Footage must also remain accessible, protected, and retrievable throughout the applicable retention period.
Part 11 controls apply where footage qualifies as a regulated electronic record and should not be assumed to be standard features of every surveillance system. Manufacturers should assess system suitability and validation requirements before relying on footage for regulated activities.
For general instructions, see SCW's guide to exporting NVR footage.
Patient Safety: Why Reliable Video Evidence Matters
For pharmaceutical manufacturers, the purpose of production video is ultimately to support product quality and patient safety. Clear footage can help QA teams detect questionable interventions, review manufacturing practices, and investigate potential risks before products reach customers and patients.
Maintaining appropriate coverage in key areas is just as important as retaining recordings. Footage that cannot clearly show the relevant activity may offer limited value, regardless of how long it is stored. Manufacturers should therefore continuously monitor system performance through appropriate checks and ensure that recording quality remains suitable for its intended purpose.
How Much Storage Does Multi-Year Pharma Retention Take?
Multi-year video retention can require substantial storage capacity.
Consider an illustrative facility with 16 fill-room cameras recording continuously at an average bitrate of 2 Mbps.
| Retention period | Approximate storage |
|---|---|
| One camera per day | 21.6 GB |
| All 16 cameras per day | 346 GB |
| 30 days | 10.4 TB |
| One year | 126 TB |
| Six years | 757 TB |
These estimates exclude RAID overhead, spare drives, backups, and other storage requirements.
The calculation is:
GB per camera per day = bitrate (kbps) × 86,400 ÷ 8,000,000
Multiply that result by the number of cameras and retention days to estimate total storage.
The most effective way to manage capacity is to reserve multi-year retention for recordings that genuinely support required records.
Use SCW's Security Camera Storage Calculator to estimate capacity based on your recording settings.
How SCW Builds Long-Term Video Storage for Pharmaceutical Facilities
SCW designs surveillance solutions around the recording, retrieval, and storage needs of each facility.
Available options include the Imperial 128-channel NVR, 16-drive Mini-SAS expansion enclosures, and 24TB surveillance-grade hard drives.
Additional considerations include:
- RAID 5 or 6 for protection against certain drive failures.
- Backup options for additional data protection.
- Quota / Allocate Space to allocate more storage to critical cameras.
- Storage expansion and system integration to support longer retention periods.
RAID is not a substitute for backup, and available capacity must account for redundancy and system overhead.
For further detailed information, explore SCW's long-term storage guidance and large storage webinar.
Frequently Asked Questions
No. FDA drug CGMP regulations do not establish a general CCTV mandate. However, FDA guidance recognizes video as a useful tool for reviewing aseptic processes. When footage supports required quality records, applicable recordkeeping and electronic record requirements may become relevant.
There is no universal period for all pharmaceutical CCTV. Footage forming part of required batch-specific records generally follows the retention period under 21 CFR § 211.180(a), while general security recordings may follow shorter policies.
Not automatically. Part 11 may apply when footage is maintained or relied upon electronically as a record required by an applicable predicate rule. Manufacturers should document which recordings support regulated activities and assess the relevant electronic record requirements.
It means retaining applicable batch records until at least one year after the batch's expiration date. For a product with a five-year shelf life, that may mean six years of retention. This does not apply to every camera in the facility.
Yes. A tiered retention policy can allocate years of storage to cameras supporting GMP records while using shorter periods for general security areas. SCW's storage allocation options can help support this approach.
The FDA questioned whether Eugia's proposed retention period would allow sufficient QA review of video footage during batch release under 21 CFR § 211.180(a). The warning letter demonstrates the importance of aligning footage retention with its documented quality-related use.
Build Video Storage Around Your QA Requirements
When production footage supports GMP records, maintaining reliable access for years may be essential.
SCW helps pharmaceutical facilities develop surveillance and storage solutions that balance critical coverage, long-term retention, and everyday security needs.
Need fill-room footage available for years? Request a Free Security Camera Floorplan or speak with an SCW expert at 828-483-4237.
Disclaimer: This page provides general information and does not constitute legal or regulatory advice. Manufacturers should consult their QA, validation, and legal teams to determine applicable requirements.